Tyra Biosciences, Inc.
TYRA
Positions held
Your positionsTYRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Tyra Biosciences is positioned in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- Tyra has a market capitalization of approximately $1.39 billion, indicating a substantial valuation in the biotech space.
- The company has a strong buy recommendation with a target mean price of $47.45, suggesting significant upside potential.
- Tyra Biosciences has not generated any revenue, which raises concerns about its sustainability and growth prospects.
- The company reported a net income loss of -45.558 million in Q2 2026, continuing a trend of negative earnings over multiple quarters.
- Tyra's score indicates a strong sell signal with a score of -24.00, reflecting bearish market sentiment and technical indicators.
Fundamentals
| Market cap | $1.37B | Enterprise value | $843.39M | Trailing P/E | — | Forward P/E | -7.21 |
| PEG | — | Price / book | 3.37 | Beta | 0.75 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -45.3% | ROA | -28.5% | Debt / equity | 0.02 |
| Current ratio | 14.91 | Free cash flow | -$63.07M | Analyst recommendation | strong_buy | Mean target | $47.45 |
| 52w high | $40.65 | 52w low | $13.29 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$45.6M | -$39.3M | -$33.8M | -$29.9M | -$28.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.0M | -$42.0M | -$36.5M | -$32.9M | -$31.5M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$120M | -$86.5M | -$69.1M | -$55.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$133M | -$104M | -$79.9M | -$58.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Raymond James Updates Healthcare Top Picks for October
2026-09-16 · Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?
2026-09-16 · Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets
2026-09-14 · Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-09-09 · Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
2026-09-09 · Tyra disappoints investors with bladder cancer data
2026-09-09 · Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
2026-09-09 · Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
2026-09-08 · Tyra Biosciences to Present at the Cantor Global Healthcare Conference
2026-09-04 · TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
Price (daily)
Full chart · RSI · MACD · patterns